Bronwen E Shaw

Summary

Country: UK

Publications

  1. ncbi Topical issues in unrelated donor haematopoietic stem cell transplants: a report from a workshop convened by the Anthony Nolan Trust in London - 2005
    R F Duarte
    The Anthony Nolan Trust, Royal Free Hospital, London, UK
    Bone Marrow Transplant 37:901-8. 2006
  2. ncbi The impact of chimerism patterns and predonor leukocyte infusion lymphopenia on survival following T cell-depleted reduced intensity conditioned transplants
    Bronwen E Shaw
    Department of Haematology, Nottingham City Hospital Campus, Nottingham University Hospitals, Nottingham UK
    Biol Blood Marrow Transplant 13:550-9. 2007
  3. ncbi Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab
    Emma P Das-Gupta
    Centre for Clinical Haematology, Nottingham University Hospitals City Campus, Nottingham, United Kingdom
    Biol Blood Marrow Transplant 13:724-33. 2007
  4. ncbi A novel technique for NOD2/CARD15 genotyping using PCR-SSP
    Neema P Mayor
    Anthony Nolan Research Institute, Royal Free Hospital, UK
    J Immunol Methods 327:82-7. 2007
  5. doi The impact of extramedullary disease at presentation on the outcome of myeloma
    Ping Wu
    Haemato Oncology Unit, Royal Marsden Hospital, Surrey, UK
    Leuk Lymphoma 50:230-5. 2009
  6. ncbi Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease
    Bronwen E Shaw
    Anthony Nolan Trust, London Royal Marsden Hospital, London Imperial College, London, UK
    Br J Haematol 153:244-52. 2011
  7. doi Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: conditioning protocols and donor selection algorithms
    B E Shaw
    Section of Haemato oncology, Royal Marsden Hospital, Belmont, Sutton, Surrey SM2 5NG, UK
    Bone Marrow Transplant 44:7-12. 2009
  8. doi Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles
    B E Shaw
    Research Department, Anthony Nolan Research Institute, Royal Free Hospital, Pond Street, Hampstead, London NW3 2QG, UK
    Leukemia 24:58-65. 2010
  9. ncbi The impact of donor factors on primary non-engraftment in recipients of reduced intensity conditioned transplants from unrelated donors
    Bronwen E Shaw
    Nottingham City Hospital, United Kingdom
    Haematologica 90:1562-9. 2005
  10. ncbi HLA-DPB1 matching status has significant implications for recipients of unrelated donor stem cell transplants
    Bronwen E Shaw
    Anthony Nolan Research Institute, London, United Kingdom
    Blood 107:1220-6. 2006

Detail Information

Publications38

  1. ncbi Topical issues in unrelated donor haematopoietic stem cell transplants: a report from a workshop convened by the Anthony Nolan Trust in London - 2005
    R F Duarte
    The Anthony Nolan Trust, Royal Free Hospital, London, UK
    Bone Marrow Transplant 37:901-8. 2006
    ....
  2. ncbi The impact of chimerism patterns and predonor leukocyte infusion lymphopenia on survival following T cell-depleted reduced intensity conditioned transplants
    Bronwen E Shaw
    Department of Haematology, Nottingham City Hospital Campus, Nottingham University Hospitals, Nottingham UK
    Biol Blood Marrow Transplant 13:550-9. 2007
    ..In conclusion, the chimerism pattern was the best indicator of improved survival in this cohort (ie, MC later converting to FDC). In those with MC, response to DLI therapy was associated with a low lymphocyte count pre-DLI...
  3. ncbi Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab
    Emma P Das-Gupta
    Centre for Clinical Haematology, Nottingham University Hospitals City Campus, Nottingham, United Kingdom
    Biol Blood Marrow Transplant 13:724-33. 2007
    ..The addition of Alemtuzumab is highly effective in preventing both rejection and severe acute and extensive chronic GVHD without an increased relapse risk...
  4. ncbi A novel technique for NOD2/CARD15 genotyping using PCR-SSP
    Neema P Mayor
    Anthony Nolan Research Institute, Royal Free Hospital, UK
    J Immunol Methods 327:82-7. 2007
    ..The assay has proven to be a rapid and accurate method of performing NOD2/CARD15 genotyping when compared to other techniques described to date...
  5. doi The impact of extramedullary disease at presentation on the outcome of myeloma
    Ping Wu
    Haemato Oncology Unit, Royal Marsden Hospital, Surrey, UK
    Leuk Lymphoma 50:230-5. 2009
    ..Patients in the EM group treated with HDT have a similar outcome to those without EM manifestations treated with HDT. HDT should form an integral component of first-line treatment for patients with EM disease whenever possible...
  6. ncbi Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease
    Bronwen E Shaw
    Anthony Nolan Trust, London Royal Marsden Hospital, London Imperial College, London, UK
    Br J Haematol 153:244-52. 2011
    ....
  7. doi Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: conditioning protocols and donor selection algorithms
    B E Shaw
    Section of Haemato oncology, Royal Marsden Hospital, Belmont, Sutton, Surrey SM2 5NG, UK
    Bone Marrow Transplant 44:7-12. 2009
    ....
  8. doi Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles
    B E Shaw
    Research Department, Anthony Nolan Research Institute, Royal Free Hospital, Pond Street, Hampstead, London NW3 2QG, UK
    Leukemia 24:58-65. 2010
    ..Conversely, our results suggest that in patients receiving an HLA-mismatched graft, the outcome is significantly better if they are also mismatched for DPB1. We recommend validation of these results in independent datasets...
  9. ncbi The impact of donor factors on primary non-engraftment in recipients of reduced intensity conditioned transplants from unrelated donors
    Bronwen E Shaw
    Nottingham City Hospital, United Kingdom
    Haematologica 90:1562-9. 2005
    ..We analyzed factors affecting primary graft failure in recipients of hematopoietic cell transplants from unrelated donors, which were performed using reduced intensity conditioning...
  10. ncbi HLA-DPB1 matching status has significant implications for recipients of unrelated donor stem cell transplants
    Bronwen E Shaw
    Anthony Nolan Research Institute, London, United Kingdom
    Blood 107:1220-6. 2006
    ..It is possible that this effect is especially apparent following TCD transplantations and invites speculation about the function of DPB1 within the immune system...
  11. doi Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant
    B E Shaw
    Department of Haematology, Royal Marsden Hospital, Institute of Cancer Research, London, UK
    Bone Marrow Transplant 42:783-9. 2008
    ..014). These data support our hypothesis that the second RIC allograft results in a lower TRM than using MA. A proportion of patients achieved a sustained remission even when relapsing after a previous MA transplant...
  12. ncbi The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation
    Bronwen E Shaw
    Anthony Nolan Research Institute, London, UK
    Blood 110:4560-6. 2007
    ..Knowledge of the DPB1 matching status prior to transplantation will aid in more precise risk stratification for the individual patient...
  13. ncbi Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant
    B E Shaw
    Section of Haemato oncology, Royal Marsden Hospital, Surrey, UK
    Bone Marrow Transplant 41:495-503. 2008
    ..In this review we summarize the outcomes of the currently available treatment modalities and discuss emerging novel approaches...
  14. ncbi Clinical importance of HLA-DPB1 in haematopoietic cell transplantation
    B E Shaw
    Department of Haematology, Nottingham City Hospital, Nottingham, UK
    Tissue Antigens 69:36-41. 2007
    ..33; P-value = <0.0001], while protecting against disease relapse (HR: 0.82, P-value = 0.01). These data support an immunogenic role for HLA-DPB1 in HCT and the need for pretransplant tissue typing at this locus...
  15. doi Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE
    Muralikrishnan Srikanth
    Haemato Oncology Unit, The Royal Marsden Hospital, Sutton, Surrey, UK
    Eur J Haematol 81:432-6. 2008
    ..In conclusion, the clinical outcome of this group of cases is poor even when treated with the intensive regimen DT-PACE; however, a subgroup can do well if DT-PACE is consolidated by ASCT...
  16. doi Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma
    Wendy Ingram
    Department of Haematological Medicine, King s College London and Kings College Hospital, London, UK
    Br J Haematol 141:235-43. 2008
    ..Furthermore, the ability to re-induce remissions with donor leucocytes provides additional benefit in favour of allogeneic HSCT...
  17. doi Diagnosis and management of acute graft-versus-host disease
    Fiona L Dignan
    Section of Haemato oncology, The Royal Marsden NHS Foundation Trust, London, UK
    Br J Haematol 158:30-45. 2012
    ..The goal of treatment should be effective control of graft-versus-host disease while minimizing risk of toxicity and relapse...
  18. doi The clinical implications of HLA mismatches in unrelated donor haematopoietic cell transplantation
    B E Shaw
    Anthony Nolan Research Institute, Royal Free Hospital, Hampstead, UK
    Int J Immunogenet 35:367-74. 2008
    ..The findings of this study have made it possible to offer advice concerning the choice of the most appropriate unrelated donor to select in order to achieve the best patient outcomes...
  19. ncbi The degree of matching at HLA-DPB1 predicts for acute graft-versus-host disease and disease relapse following haematopoietic stem cell transplantation
    B E Shaw
    Anthony Nolan Research Institute, Royal Free Hospital, London, UK
    Bone Marrow Transplant 31:1001-8. 2003
    ..This study provides further evidence for an immunogenic role of HLA-DPB1 in HSC transplants...
  20. doi Organ-specific management and supportive care in chronic graft-versus-host disease
    Fiona L Dignan
    Section of Haemato oncology, The Royal Marsden NHS Foundation Trust, London, UK
    Br J Haematol 158:62-78. 2012
    ..The goal of treatment should be effective control of GvHD while minimizing the risk of toxicity and relapse...
  21. pmc Association of functional polymorphisms of the transforming growth factor B1 gene with survival and graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation
    Mariano Berro
    Anthony Nolan Research Institute, Anthony Nolan Trust, Fleet Road, NW3 2QG, London, UK
    Haematologica 95:276-83. 2010
    ..Transforming growth factor beta1 is a member of a highly pleiotrophic family of growth factors involved in the regulation of numerous immunomodulatory processes...
  22. doi High readmission rates are associated with a significant economic burden and poor outcome in patients with grade III/IV acute GvHD
    Fiona L Dignan
    Section of Haemato oncology, The Royal Marsden NHS Foundation Trust, Sutton, UK
    Clin Transplant 27:E56-63. 2013
    ..038). Survival was higher in those with grade I/II GvHD (55%) compared to grade III/IV GvHD (14%; p < 0.001). This study shows the high economic burden and poor overall survival associated with grade III/IV GvHD...
  23. ncbi Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated donors
    Neema P Mayor
    Anthony Nolan Research Institute, Royal Free Hospital, London, United Kingdom
    J Clin Oncol 25:4262-9. 2007
    ....
  24. pmc Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission
    Bella Patel
    Department of Haematology, Royal Free and University College London Medical School, and BSBMT Data Registry, Guy s Hospital, London, UK
    Haematologica 94:1399-406. 2009
    ..Although T-cell depletion abrogates graft-versus-host disease, the impact on disease-free survival in acute lymphoblastic leukemia is not known...
  25. doi The impact of HLA genotyping on survival following unrelated donor haematopoietic stem cell transplantation
    Bronwen E Shaw
    Research Department, Anthony Nolan Research Institute, London, UK
    Br J Haematol 150:251-8. 2010
    ..e. matched for HLA-A, -B, -C, -DRB1, however, in certain circumstances, mismatches may be tolerated and/or permissive...
  26. pmc Cord blood stem cells for hematopoietic stem cell transplantation in the UK: how big should the bank be?
    Sergio Querol
    Anthony Nolan Research Institute, Royal Free Hospital, Pond Street, London NW32QG, UK
    Haematologica 94:536-41. 2009
    ..We carried out a study to define the optimal size of a national cord blood bank for the UK...
  27. ncbi The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma
    Bronwen E Shaw
    Anthony Nolan Research Institute, London, UK
    Br J Haematol 123:886-95. 2003
    ....
  28. doi Diagnosis and management of chronic graft-versus-host disease
    Fiona L Dignan
    Section of Haemato oncology, The Royal Marsden NHS Foundation Trust, London, UK
    Br J Haematol 158:46-61. 2012
    ..The goal of treatment should be the effective control of GvHD while minimizing the risk of toxicity and relapse...
  29. ncbi Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease
    Mark J Bishton
    Department of Haematology, Nottingham City Hospital, Nottingham, UK
    Br J Haematol 136:752-61. 2007
    ..We conclude that IVE has a high response rate across a range of refractory and relapsed lymphoma with acceptable toxicity and excellent PBSC mobilising characteristics...
  30. ncbi Histologic features of the liver biopsy predict the clinical outcome for patients with graft-versus-host disease of the liver
    Rafael F Duarte
    Department of Haematology, Royal Free and University College Medical School, London, United Kingdom
    Biol Blood Marrow Transplant 11:805-13. 2005
    ..Prospective validation of our findings is warranted...
  31. ncbi Improving the outcome of unrelated donor stem cell transplantation by molecular matching
    B E Shaw
    Anthony Nolan Research Institute, Hampstead, UK
    Blood Rev 15:167-74. 2001
    ....
  32. pmc NOD2 Polymorphisms and Their Impact on Haematopoietic Stem Cell Transplant Outcome
    Neema P Mayor
    Anthony Nolan Research Institute, Royal Free Hospital, Pond Street, London NW3 2QG, UK
    Bone Marrow Res 2012:180391. 2012
    ..Here, we will review the existing literature, summarise current theories as to why the data differs, and suggest possible mechanisms by which the SNPs affect HSCT outcome...
  33. doi Donor safety: the role of the WMDA in ensuring the safety of volunteer unrelated donors: clinical and ethical considerations
    B E Shaw
    Department of Haematology, Anthony Nolan Trust, Royal Free Hospital, London, UK
    Bone Marrow Transplant 45:832-8. 2010
    ..One of the principal goals leading to the formation of the World Marrow Donor Association (WMDA) was to establish internationally acceptable standards for all aspects of unrelated donor care...
  34. ncbi Clinical profile and outcome of urotheliotropic viral haemorrhagic cystitis following haematopoietic stem cell transplantation: a 7-year tertiary centre analysis
    Parameswaran Anoop
    Department of Haematology, Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, UK
    Hematology 16:213-20. 2011
    ..Severe HC contributed to the deaths of two patients. Overall survival was not statistically different between patient subgroups with non-severe and severe HC...
  35. ncbi Clinical impact of MRSA in a stem cell transplant unit: analysis before, during and after an MRSA outbreak
    B E Shaw
    Department of Clinical Haematology, Nottingham University Hospitals, Nottingham, UK
    Bone Marrow Transplant 39:623-9. 2007
    ..In conclusion, MRSA is likely to remain endemic in our unit, but robust early screening protocols and aggressive eradication strategies have effectively limited the spread of and morbidity due to this pathogen...
  36. doi An early CT-diagnosis-based treatment strategy for invasive fungal infection in allogeneic transplant recipients using caspofungin first line: an effective strategy with low mortality
    F L Dignan
    Section of Haemato oncology, Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK
    Bone Marrow Transplant 44:51-6. 2009
    ..These data suggest that this non-empirical strategy may be feasible and that caspofungin may be effective in this setting. A randomized controlled trial is warranted to further assess these results...
  37. ncbi Polymorphisms in the TNFA gene promoter region show evidence of strong linkage disequilibrium with HLA and are associated with delayed neutrophil engraftment in unrelated donor hematopoietic stem cell transplantation
    B E Shaw
    Anthony Nolan Research Institute, Royal Free Hospital, Pond Street, Hampstead, London NW3 2QG, UK
    Tissue Antigens 63:401-11. 2004
    ..Our results suggest a functional effect of TNFA polymorphisms on myeloid engraftment in unrelated HSCT...
  38. ncbi Immunogenetic factors in donors and patients that affect the outcome of hematopoietic stem cell transplantation
    Alejandro Madrigal
    The Anthony Nolan Research Institute, Royal Free Hospital London, UK
    Blood Cells Mol Dis 40:40-3. 2008
    ..Genotyping recipients and donors prior to transplant may present valuable information for planning and management of pre-transplant conditioning regimens, and for prognosis of the outcome...